Suppose you’re referring to the drug Aduhelm (or similar monoclonal antibody treatments). The Centers for Medicare & Medicaid Services approved coverage in April 2022 for Alzheimer’s patients involved in a clinical trial of the drug.Once the FDA has determined that it works, the CMS will re-evaluate and likely expand that coverage to all Alzheimer’s patients.